#United States #New York #Securities Fraud #Pomerantz LLP #Inspire Medical

In an alarming turn of events, Pomerantz LLP has initiated an investigation on behalf of investors in Inspire Medical Systems, Inc. (NYSE: INSP). This scrutiny is focused on potential securities fraud that may have involved the company and its executives. Investors holding shares of Inspire Medical Systems are encouraged to reach out to the firm's attorney, Danielle Peyton, for more information regarding their rights and possible actions. The investigation comes in light of significant downward adjustments made by Inspire concerning its financial projections. On August 4, 2025, the company disclosed its second quarter financial performance, revealing a reduction in the revenue outlook for the entire fiscal year. Inspire downgraded its anticipated revenue from a range of $940 million to $955 million down to an estimated $900 million to $910 million. The company also modified its expected diluted net income per share from the previously projected $2.20 - $2.30 to a new estimate of $0.40 - $0.50. The revisions were attributed primarily to delays in the commercial launch of Inspire’s next-generation Inspire V neurostimulation system. Following the announcement of these figures, Inspire Medical's stock witnessed a severe decline, plummeting by $42.04 per share, a staggering 32.35%, to settle at $87.91 among investors. Pomerantz LLP, with a historical reputation in handling corporate, securities, and antitrust class cases, is recognized for its rigorous pursuit of justice for shareholders. Founded by Abraham L. Pomerantz, a pioneering figure in class action litigation, the firm is known for recovering substantial damages for clients affected by securities fraud or corporate misbehavior. They have maintained this legacy for over 85 years, continuously working diligently to safeguard the rights of affected investors. Investors wishing to participate in the inquiry or those with claimable evidence are advised to ensure they act swiftly to connect with Pomerantz LLP. To join a potential class action or to gain further insights regarding this investigation, individuals can reach out via the provided contact information: Danielle Peyton at Pomerantz LLP through [email protected] or by calling 646-581-9980, ext. 7980. Legal proceedings of this nature often necessitate quick responses, underscoring the importance for affected investors to be proactive. The impact of these changes on investor confidence and the potential ramifications for Inspire Medical Systems will be observed closely by both the market and legal experts alike. Stakeholders should remain vigilant as the situation unfolds and further developments arise from this ongoing investigation.